Free Trial
→ Think NVDA’s run was epic? You ain’t seen nothin’ yet (From Timothy Sykes) (Ad)
NASDAQ:RENB

Renovaro 5/15/2024 Earnings Report

Renovaro logo
$0.34 +0.03 (+8.53%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$0.34 +0.00 (+0.03%)
As of 06:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings History

Renovaro EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Renovaro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Renovaro Announcement Details

Quarter
Date
5/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Renovaro's Q3 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Renovaro Earnings Headlines

RENB-aandeel raakt 52-weeks dieptepunt van $ 0,32 door marktuitdagingen
May 1, 2025 | nl.investing.com
Renovaro BioSciences expands collaboration with Nebul
April 23, 2025 | markets.businessinsider.com
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
May 5, 2025 | Golden Portfolio (Ad)
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
April 22, 2025 | globenewswire.com
Renovaro riskeert Nasdaq-notering te verliezen door te lage aandelenkoers
April 18, 2025 | nl.investing.com
Renovaro BioSciences, BioSymetrics close merger transaction
April 9, 2025 | markets.businessinsider.com
See More Renovaro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Renovaro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Renovaro and other key companies, straight to your email.

About Renovaro

Renovaro (NASDAQ:RENB), a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

View Renovaro Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles